Ascension completes sale of 8 Illinois hospitals to Prime Healthcare for more than $370 million
Ascension has officially sold eight of its Illinois hospitals to a California-based health system for more than $370 million.
Prime Healthcare said Saturday that a previously announced deal had closed to buy the hospitals, along with four Illinois senior living and post-acute care facilities and physician practices from Ascension.
The hospitals are all generally keeping their names but without the Ascension branding. The hospitals are: Holy Family Medical Center in Des Plaines, Mercy Medical Center in Aurora, Resurrection Medical Center in Chicago, Saint Francis Hospital in Evanston, Saint Joseph Medical Center in Joliet, Saint Joseph Hospital in Elgin, Saint Mary's Hospital in Kankakee and Saint Mary of Nazareth Hospital in Chicago.
Saint Elizabeth in Chicago was also part of the deal, but Ascension previously announced plans to close the hospital, which sits on the city's West Side, has 28 beds and treats acute mental illness. Ascension said in an application to the state Health Facilities and Services Review Board that nearby Saint Mary of Nazareth could take Saint Elizabeth's patients. Ascension transferred Saint Elizabeth's services to Saint Mary on Feb. 17, Prime said in a statement.
Until now, the hospitals have been not-for-profit as part of Ascension, which is a large Catholic health system with hospitals across the country. As part of Prime, most of the hospitals are becoming for-profit, while Saint Francis in Evanston and Saint Mary's in Kankakee will keep their not-for-profit statuses as part of Prime's affiliated charity called the Prime Healthcare Foundation.
The hospitals will continue to be affiliated with the Catholic Church, Prime said in a news release Saturday.
Prime has offered employment to 'substantially all' of the facilities' workers, and has said it will invest $250 million in the Illinois facilities for upgrades, capital improvements, technology and system upgrades.
'We're very confident we can turn around these facilities and maintain them as assets to the communities,' Dr. Sunny Bhatia, Prime's president and chief medical officer, told members of the Illinois Health Facilities and Services Review Board at their meeting in December. 'We're here to stay. … This is what we do. We save distressed community hospitals.'
Bhatia said every hospital that Prime has acquired has been in financial distress at the time of acquisition.
The hospitals are Prime's first ones in Illinois. Prime has 51 hospitals and nearly 57,000 employees and affiliated physicians across the U.S.
The state Health Facilities and Services Review Board voted unanimously in December to approve the deal.
The approval came despite opposition from the National Nurses United union, which in an October letter to the board, cited, 'Prime Healthcare's history of putting profits over patients, leading to illegal and unethical practices that risk people's health, in addition to the elimination of crucial health services in the community.'
Dr. Prem Reddy, Prime's chairman and CEO, agreed in 2018 to pay the government $65 million to settle allegations that 14 Prime hospitals in California knowingly submitted false claims to Medicare by admitting patients to hospitals who weren't in need of inpatient care, and by billing Medicare for more expensive diagnoses than the patients actually had. In 2021, Prime, Reddy and one of Prime's doctors agreed to pay $37.5 million to settle allegations that Prime paid the doctor kickbacks for patient referrals, among other allegations.
Prime did not admit any liability as part of those agreements.
Ascension is keeping a number of its other Illinois hospitals for now. Ascension spent nearly two years doing due diligence to make sure Prime was the best buyer for its hospitals, said Ascension Illinois CEO Polly Davenport, at the Health Facilities and Services Review Board meeting in December. She said Ascension decided selling some of its hospitals 'was the most reasonable path to ensuring our care continues to flourish.'
Ascension posted a $1.8 billion operating loss for the year that ended June 30, though that was an improvement from the organization's $3 billion operating loss the prior year.
This is the third time the Ascension hospitals have changed ownership in a decade — a lot of change, even for the Chicago area where hospital mergers and acquisitions are common. The hospitals were once part of Presence Health, and then, in 2018, became part of Amita Health. Ascension and AdventHealth unwound their Amita Health partnership in 2022, and the hospitals were then Ascension Illinois hospitals.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
an hour ago
- New York Post
NY state Senate approves doctor-assisted suicide bill, sends it to Hochul's desk for approval
ALBANY – State Senate Democrats passed highly controversial legislation that would allow terminally ill people to take their own lives with the help of doctors in a razor-thin vote Monday — leaving it up to Gov. Kathy Hochul whether to sign it into law. 'This is one of the great social reforms of our state,' state Sen. Brad Hoylman-Sigal (D-Manhattan), the bill's sponsor in the upper chamber, touted at a press conference earlier in the day Monday — putting the measure on the same tier as the legalization of gay marriage. 'This is about personal autonomy, this is about liberty, this is about exercising one's own freedom to control one's body,' Hoylman-Sigal continued. 3 The 'Medical Aid in Dying Act' passed the state senate Monday evening, meaning it only needs Gov. Kathy Hochul's signature to become law. Vaughn Golden The measure passed 35 to 27, with six Democrats – Senators April Baskin, Siela Bynoe, Cordelle Cleare, Monica Martinez, Roxanne Persaud, and Sam Sutton – voting against it. 'The governor will review the legislation,' a spokesperson for Hochul said. The bill's passage follows a years-long campaign that was fought tooth and nail by a diverse group of critics, including disability rights activists and the Catholic church, as well as many black and Orthodox Jewish communities. 'The Governor still has the opportunity to uphold New York's commitment to suicide prevention, protect vulnerable communities, and affirm that every life—regardless of disability, age, or diagnosis—is worthy of care, dignity, and protection,' The New York Alliance Against Assisted Suicide wrote in a statement following the vote. A Catholic group slammed the bill's passing as 'a dark day for New York' and also called on Hochul to refuse to sign it. 'For the first time in its history, New York is on the verge of authorizing doctors to help their patients commit suicide. Make no mistake – this is only the beginning, and the only person standing between New York and the assisted suicide nightmare unfolding in Canada is Governor Hochul,' Dennis Poust, Executive Director of the New York State Catholic Conference, wrote in a statement. 3 The state Senate voted 35-27 Monday night to legalize physician-assisted suicide for people with terminal illnesses. AP Ahead of the vote, the nearly three-hour debate on the Senate floor got emotional, with several lawmakers holding back tears as they explained their votes. Syracuse-area state Sen. Rachel May (D-Onondaga) shared the story of her late husband, who was receiving morphine in the final stages of his battle with cancer, which he eventually succumbed to at 32 years old. 'I don't know if the last largest dose he took also took his life, but I know that he died in peace,' May said. 'It isn't about controlling the disease or controlling the pain, it's about having control at the end of your life,' she said before voting in favor. Critics fear the legislation lacks critical safeguards over how doctors approve patients looking to receive the prescription for a lethal cocktail of drugs, such as a statutory waiting period, establishing clear chain of custody for the pills, mandating the doctor and recipient meet in-person, and requiring a disclosure that someone indeed used the drugs to take their own life. Under the bill, recipients would need approval from two doctors and a sign-off from two independent witnesses, after which they would receive a prescription for drugs they could use to take their life at a time of their choosing. 3 Gov. Kathy Hochul has not signaled whether she will sign the assisted suicide bill. Lev Radin/ZUMA / Doctors also do not have to conduct a mental health screening for each patient, but may refer a patient for one under the legislation. 'I don't think requesting end-of-life medication when an individual is suffering and in pain and dying suggests a mental health condition, if anything, I think it's quite rational,' Hoylman-Sigal said. Hoylman vowed the bill would not lead to such 'unintended consequences.' 'It was a professional organization that provided us crucial guidance, that helped us develop the state-of-the-art safeguards in this legislation that gave my colleagues and the general public, I believe, the assurance that there will not be unintended consequences,' he said. The legislation is referred to by its supporters as the 'Medical Aid in Dying' bill. 'The option of medical aid in dying provides comfort, allowing those who are dying to live their time more fully and peacefully until the end. I am profoundly grateful to Senate Majority Leader Stewart-Cousins for giving her conference the space to have this important and emotional discussion,' Corinne Carey, Senior Campaign Director of Compassion and Choices, the main group driving the effort to pass the bill, wrote in a statement.
Yahoo
an hour ago
- Yahoo
Canadian doctor after devastating Sudan assignment: 'The worst humanitarian crisis in the world'
Sudan is facing an emergency of staggering proportions, one that has displaced over 12 million people and decimated the nation's healthcare system. But unlike other global crises, this one seems to be happening almost entirely in silence. 'This is not just a war between two parties,' says Sana Bég, executive director of Médecins Sans Frontières (MSF) Canada. 'It's a war on the people of Sudan.' What began as a power struggle between the Sudanese Armed Forces (SAF) and the Rapid Support Forces (RSF) in April 2023 has spiralled into what aid workers now describe as the world's largest displacement crisis. According to the World Health Organization, 70 to 80 per cent of the country's healthcare facilities are either nonfunctional or overwhelmed. In parts of Darfur, even the UN is absent, leaving MSF — also known as Doctors Without Borders — as the only international organization delivering aid on the ground. 'Having to choose between one life-saving activity for another are the kinds of decisions our teams are left to make because of this increasingly isolated environment where we're the only ones being relied on to carry out an entire scope of what should be an ecosystem of aid,' Bég says. This is not just a war between two parties. It's a war on the people of Sudan. For Dr. Reza Eshaghian, a Vancouver-based physician who recently returned from Darfur, the devastation is unlike anything he has seen before. 'What's happening in Sudan is the worst humanitarian crisis in the world, full stop,' he says. 'There are bombings, sexual violence, armed robbery. There's a lack of protection and international humanitarian law.' Eshaghian, who began working with MSF in 2014, was stationed in Nyala, a city in South Darfur. He noted that it's not just the violence itself that is killing people: 'So much of the suffering and death is from preventable illness. We saw women dying from eclampsia and postpartum hemorrhage. People are dying of malaria, malnutrition, diarrhea, dehydration, sepsis. These are things we know how to treat, but there's no infrastructure left to do it.' The hospital Eshaghian helped support saw overwhelming gaps in supplies and staffing. Although MSF brings in its own equipment, the logistics are gruelling, and his team saw supply shipments often delayed. There was also never enough. People are dying of malaria, malnutrition, diarrhea, dehydration, sepsis. These are things we know how to treat, but there's no infrastructure left to do it. Despite the danger, MSF has continued to provide help where it can, but the work has come at immense personal cost, especially for local staff. 'Eighty percent of our workforce globally is locally hired,' Bég notes. 'These are people whose homes are war zones. [They] tell us they have a fear of retaliation or repercussions for any actions that could be interpreted as siding with one warring party or the other. Having to live in fear on a regular basis is far different than what some of our teams that have the ability to get on a plane and leave face.' In other words, simply providing medical care can be seen as a political act. But that doesn't make it any more secure. The safety protocols MSF follows — clearly marked medical uniforms, identified facilities — are no longer a guarantee. 'We used to rely on international humanitarian law to protect aid workers and patients,' she says. 'That's not the reality anymore. Not in Sudan. The sad reality now is that we are no longer able to guarantee safety in the countries that we're operating in, so we're taking it day by day.' Among the most at-risk in Sudan, as is often the case in most war zones, are women and children. In one year alone, MSF supported approximately 8,500 births and performed over 1,600 emergency C-sections across Sudan. 'But the numbers don't tell the full story,' Bég says. 'We're talking about women walking 100 kilometres on foot, often pregnant or with sick children, just to reach care.' Eshaghian recalls one such woman who fled violence in Khartoum and arrived in Nyala with her three-year-old daughter — the last surviving member of her family. 'Her child had a fever. We were able to treat her. But the mother had lost her husband and other children along the way. Everything had been taken from them. And there are endless stories like this one." In many cases, the trauma goes even deeper. MSF staff are seeing widespread evidence of sexual violence being used as a weapon of war. 'Women have been raped while fleeing,' Bég says. 'Survivors end up giving birth to babies born out of rape, then they have to deal with the shame and fear of stigma and retaliation.' The scale of the trauma has pushed MSF to adopt community-based care models that, for example, can look like training trusted women in each village to serve as peer counsellors and connectors to formal care. 'We can't be everywhere,' Bég says. 'But we can empower people to help each other.' Both Bég and Eshaghian say that the world's silence on Sudan is not accidental — it's systemic. 'There are no foreign correspondents in Sudan. No international media,' Bég says. 'We are the eyes to the world, and we see that as a responsibility to speak out about what we're seeing and to call for an urgent scaling of aid.' That lack of visibility means less pressure on governments and organizations like the UN to act. 'UNICEF, UNFPA — their response is small and, in the case of Darfur, they're barely present,' Eshaghian says. 'There's clearly a lack of political and diplomatic pressure from governments who have the power to push for the end of this war.' Bég doesn't mince words. She asks, 'Who gets the privilege of our attention? There are certain conflicts that make it to our feeds, to our social media, to the news. There is an inherent inequity and racism in that itself. Where you live shouldn't determine whether you live, and that is what we're seeing in Sudan — willful ignorance.' Where you live shouldn't determine whether you live. Still, there are reasons to keep going — glimpses of joy, even in the bleakest corners. 'When you visit patients in the hospital, especially children who bounce back from illness and are quite resilient, you see their happiness. [We] took a lot of pride in ... being able to support the community, to see the impact,' Eshaghian says. What MSF is now demanding is clear: A significant increase in humanitarian access, stronger diplomatic pressure on Sudan's warring factions, and more support from countries like Canada. 'Our patients have no choice but to wake up with hope every day,' Bég says. 'The least we can do is show up for them and provide care. Hope is not optional, it's our moral imperative. We have to reject apathy.'
Yahoo
2 hours ago
- Yahoo
China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
First global filing for potentially best-in-class TGCT treatment based on strong positive data from Phase 3 MANEUVER study Potential for pimicotinib to be first systemic TGCT therapy approved in China, following recent granting of Priority Review by CDE Additional applications planned in the US and other markets around the world Not intended for UK-based media DARMSTADT, Germany, June 10, 2025--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company's application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to pimicotinib by the CDE in May for the treatment of patients with TGCT who require systemic therapy, which is expected to expedite the review process. Pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., also has been granted breakthrough therapy designation (BTD) by the NMPA. "With the acceptance of our application for pimicotinib and the initiation of the priority review, we aim to offer patients in China the first approved systemic therapy for TGCT, addressing a tremendous unmet need in this country," said Hong Chow, Head of China and International, Healthcare business of Merck KGaA, Darmstadt, Germany. "Pimicotinib has demonstrated the ability to not only shrink tumors that affect their joints but also improve outcomes like mobility, pain and stiffness, highlighting its potential to be a best-in-class treatment for TGCT. In parallel, we are working to file a New Drug Application to the US Food and Drug Administration, with additional filings planned in other markets." TGCT is a locally aggressive and often recurring tumor of the joints that can cause high morbidity associated with swelling, pain, stiffness, and limited mobility of the affected joints, significantly impacting daily activities and quality of life in the primarily working-age population that it affects. If left untreated or in recurrent cases, TGCT can result in irreversible damage to the bone, joint and surrounding tissues. This highlights the need for well-tolerated and effective systemic treatments that can impact tumor growth while relieving the symptoms of the disease. The application is based on results from Part 1 of the global Phase 3 MANEUVER study, in which once-daily pimicotinib demonstrated a statistically significant improvement in the primary endpoint of objective response rate (ORR) assessed by blinded independent review committee (BIRC) compared with placebo at week 25 (54.0% vs. 3.2% for placebo; p<0.0001). The study also demonstrated statistically significant and clinically meaningful improvements in all secondary endpoints related to key patient-reported outcomes in TGCT, including improvements in active range of motion and physical function and reductions in stiffness and pain. The data were presented earlier this month at the 2025 ASCO Annual Meeting. About MANEUVERThe pivotal Phase 3 MANEUVER study is a three-part, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pimicotinib in patients with TGCT who require systemic therapy and have not received prior anti-CSF-1/CSF-1R therapy. The study is being conducted by Abbisko Therapeutics in China (n=45), Europe (n=28), and the US and Canada (n=21). In the double-blind Part 1, 94 patients were randomized 2:1 to receive either 50 mg QD of pimicotinib (n=63) or placebo (n=31) for 24 weeks. The primary endpoint is objective response rate (ORR) at week 25, as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review in the intent-to-treat (ITT) population. Secondary endpoints include tumor volume score, active range of motion, stiffness by Numeric Rating Scale (NRS), pain by Brief Pain Inventory (BPI), and physical function measured by Patient-Reported Outcomes Measurement Information System (PROMIS). After the double-blind Part 1, eligible patients could continue to the open-label Part 2 for up to 24 weeks of dosing, results of which are expected in mid-2025. Patients who complete Part 2 may then enter the open-label extension phase (Part 3) for extended treatment and safety follow-up. About Pimicotinib (ABSK021)Pimicotinib (ABSK021), which is being developed by Abbisko Therapeutics, is a novel, orally administered, highly selective and potent small-molecule inhibitor of CSF-1R. Pimicotinib was recently granted Priority Review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of patients with tenosynovial giant cell tumor (TGCT) who require systemic therapy. Pimicotinib has been granted breakthrough therapy designation (BTD) by China National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA), and priority medicine (PRIME) designation from the European Medicines Agency (EMA). Merck KGaA, Darmstadt, Germany, holds worldwide commercialization rights for pimicotinib. Advancing the Future of Cancer CareAt Merck KGaA, Darmstadt, Germany, we strive every day to improve the futures of people living with cancer. Building on our 350-year global heritage as pharma pioneers, we are focusing our most promising science to target cancer's deepest vulnerabilities, pursuing differentiated molecules to strike cancer at its core. By developing new therapies that can help advance cancer care, we are determined to create a world where more cancer patients will become cancer survivors. Learn more at About Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to to register for your online, change your selection or discontinue this service. View source version on Contacts Media Relations Phone: +1 (781) 427-4351 Investor Relations Phone: +49 6151 72-3321 Sign in to access your portfolio
